At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 88 enrolled
Drug / intervention
BGB-290drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China
In Brief
A Phase 2 clinical trial evaluating BGB-290 for HER2-negative Breast Cancer. Completed, enrolled 88 participants across 20 sites.
Detailed Summary
This is a Phase 2, open-label, multi-center study of BGB-290 administered orally (PO) twice daily (BID) in adult Chinese patients with advanced HER2(-) breast cancer harboring germline BRCA mutation, which have progressed despite standard therapy, or for which no standard therapy exists.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHER2-negative Breast Cancer
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartJun 2018
First PostedJul 2018
Primary CompletionOct 2020
Study CompletionApr 2021
TodayJul 2026
First PostedJul 2, 2018
Enrollment StartJun 22, 2018
Primary CompletionOct 9, 2020
Study CompletionApr 14, 2021
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 8 years ago
Interventions
BGB-290drug
Administered orally